Ignis Therapeutics announced that it has received $180 million in funding from 6 Dimensions Capital, L.P., Ruentex Group, KB Investment Co., Ltd., Mubadala Investment Company PJSC, HBM Healthcare Investments Ltd., The Goldman Sachs Group, Inc. and another investor
Ignis Therapeutics announced that it has received $180,000,000 in its series A round of funding led by new investor, 6 Dimensions Capital, L.P. on November 11, 2021. The transaction also included participation from Ruentex Group, KB Investment Co., Ltd., WTT Investment, Mubadala Investment Company PJSC, HBM Healthcare Investments (Cayman) Ltd. and The Goldman Sachs Group, Inc.